Keywords
How to Cite
Abstract
The article presents a comparative analysis of clinical and morphological characteristics of tumor process in patients with breast cancer and endometrial cancer with diabetes mellitus and without it. Previously little-known features of the tumor process in combination with diabetes were revealed. The data obtained indicated that in case of breast cancer the presence of diabetes for a number of signs influenced the course/characteristics of the disease: e.g., the tumor size was significantly greater than in patients without diabetes and highly differentiated Gltumors were less common. In case of endometrial cancer, diabetes (but only in combination with obesity or postmenopausal period) was combined with more favorable characteristics of tumor indicating a diagnosis-specific effect of Type 2 diabetes in regard of the tumor process features. An evaluation of the role of antidiabetic therapy variant discovered that in patients with breast cancer metformin therapy was combined with more frequent detection of highly differentiated, hormone-positive tumors, which was not revealed in patients with endometrial cancer.References
Берштейн Л.М. онкоэндокринология: традиции, современность и перспективы. - СПб.: наука, 2004. - 343 с.
Берштейн Л.М. Эпидемиология, патогенез и пути профилактики рака эндометрия: стабильность или эволюция? // Практ.онкол. - 2004. - Т. 5 - № 1. - С. 3-8.
Берштейн Л.М., Берлев И.В., Васильев Д.А., Балтрукова А.Н. и др. ожирение и особенности рака эндометрия: меняется ли что-нибудь с годами? // Вопр. онкол. - 2015. - Т. 61. - № 4. - С. 575 -579.
Берштейн Л.М., Порошина Т.Е., Коваленко И.М., Васильев Д.А. Сравнение уровня маркера повреждения ДНК 8-гидрокси-2> -дезоксигуанозина в сыворотке крови больных раком молочной железы и эндометрия, страдающих или не страдающих сахарным диабетом // Бюллетень экспериментальной биологии и медицины. - 2016. - Т. 161. - № 4. - С. 538-541.
Бохман Я.В. Руководство по онкогинекологии. - Л.: Медицина, 1989. - 464 с.
Дедов И.И., Шестакова М.В. Сахарный диабет (руководство для врачей). - М.: Медицинское информационное агентство, 2011. - 808 с.
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. - М. 2016. - 236 с.
Семиглазов В.Ф, Топузов Э.Э. Рак молочной железы. - М.: Медпресс-информ, 2009. - 172 с.
Чернышова А.Л. Прогноз и особенности клинического течения рака эндометрия на фоне метаболического синдрома. - Дисс.. на соиск. уч. степ. д.м.н. // Томск, 2009.
Aizen D., Sarfstein R., Bruchim I. et al. Proliferative and signaling activities of insulin analogues in endometrial cancer cells // Mol Cell Endocrinol. - 2015. - Vol. 406. - P 27-39.
Arem H., Irwin M. Obesity and endometrial cancer survival: a systematic review // Int. J. Obes. - 2013. - Vol. 37(5). - P. 634-639.
Berstein L.M., Boyarkina M.P, Tsyrlina E.V. et al. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin // Med Oncol. - 2011. - Vol. 28(4). - P. 1260-1263.
Billingsley C.C., Cansino C., O'Malley D.M. et al. Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI // Gynecol. Oncol. - 2016. - Vol. 140 (3). - P 405-408.
Branca F., Nikogosian H., Lobstein T. Проблема ожирения в Европейском регионе ВОЗ и стратегия ее решения // Копенгаген: Европейское региональное бюро ВОЗ, 2009. - 408 с.
Buschard K., Thomassen K., Lynge E. et al. Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort // Cancer Causes Control. - 2017. - Vol. 28 (1). - P. 13-21.
Currie C.J., Poole C.D., Evans M. et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes // J. Clin. Endocrinol. Metab. - 2013. - Vol. 98 (2). -P. 668-677.
De Barros Machado A., Dos Reis V., Weber S. et al. Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment // Oncol. Lett. - 2016. - Vol. 12 (5). - P. 3626-3632.
Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. - Geneva. 2008. - 46 p.
Gadducci A., Biglia N., Tana R. et al. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning // Crit. Rev. Oncol. Hema-tol. - 2016. - Vol. 105. - P 73-83.
Gründker C., Günthert A.R., Emons G. Hormonal heterogeneity of endometrial cancer // Adv. Exp. Med. Biol. - 2008. - Vol. 630. - P. 166-188.
Mountzios G., Pectasides D., Bournakis E. Developments in the systemic treatment of endometrial cancer // Crit. Rev. Oncol. Hematol. - 2011. - Vol. 79(3). - P. 278292.
Seebacher V., Bergmeister B., Grimm C. et al. The prognostic role of metformin in patients with endometrial cancer: a retrospective study // Eur. J. Obstet. Gynecol. Reprod. Biol. - 2016. - Vol. 203 - P. 291-296.
Setiawan V.W., Yang H.P., Pike M.C. et al. Type I and II endometrial cancers: have they different risk factors? // J. Clin. Oncol. - 2013. - Vol. 31(20). - P. 2607-2618.
Soliman P.T., Zhang Q., Broaddus R.R. et al. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study // Gynecol. Oncol. - 2016. - Vol. 143(3). - P. 466-471.
Srokowski T.P., Fang S., Hortobagyi G.N. et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer // J. Clin. Oncol. - 2009. - Vol. 27. - P. 2170-2176.
Svenson U., Nordfjäll K., Stegmayr B. et al. Breast cancer survival is associated with telomere length in peripheral blood cells // Cancer Res. - 2008. - Vol. 68 (10). - P 3618-3623.
Van de Poll-Franse L.V., Houterman S., Janssen-Heijnen M.L. et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis // Int. J. Cancer. - 2007. - Vol. 120. - P 1986-1992.
Weinstein D., Simon M., Yehezkel E. et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells // Diabetes Metab. Res. Rev. - 2009. - Vol. 25 (1). - P 41-49.
Yung R.L., Ligibel J.A. Obesity and breast cancer: risk, outcomes, and future considerations // Clin. Adv. Hematol. Oncol. - 2016. - Vol. 14 (10). - P 790-797.
Zhao Y, Zheng X., Zhang H. et al. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis // Chem. Biol. Interact. - 2015. - Vol. 240. - P 310-315.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017